Every day, about 10 men die in Poland due to prostate cancer. Fear of losing sexual function and other ailments that worsen quality of life often prevents men not only from undergoing diagnostic tests, but also from undertaking appropriate treatment of prostate cancer. Meanwhile, the detection of a prostate tumor only limited to the prostate gland provides a much better chance for a complete cure. It also allows using highly effective and at the same time less invasive methods of prostate cancer treatment.

Prostate cancer is the second most common cancer in men, and its incidence increases with age. It is estimated that after the age of 75 years 80% to 90% of men are "carriers" of this cancer. Typically, these are cases of the so-called latent cancer that does not cause serious clinical symptoms and does not require treatment. Usually, in the early stages of the disease, it does not show any clinical signs or symptoms. Diagnostics of prostate cancer involve a basic diagnostic "triad" which includes the following:

• per rectum examination, which in most cases allows to find hard nodules located in the prostate, which may suggest the presence of cancer
• determining the PSA (prostate specific antigen) level in the serum, which exceeding 4 ng/l may suggest the presence of cancer
• transrectal ultrasound (TRUS) with a prostatic core-needle biopsy and histopathological evaluation of sampled material together with assessing a Gleason score. There are 10 degrees of the Gleason scale, the higher the score, the worse the prognosis, as well as tests such as bone scintigraphy, computed tomography, NMR, and PET. They allow to assess the severity of the disease, which determines the choice of treatment method.

Patients interested in laparoscopic radical prostatectomy and HIFU treatment are invited to consult a physician at the HiFU Clinic.